Breakthrough In Acute Pain Management: FDA Approves First-In-Class Non-Opioid
On Thursday, the U.S. Food and Drug Administration (FDA) approved Journavx (suzetrigine) 50 mg oral tablets, a first-in-class non-opioid analgesic for...
Last updated: 2026-01-09 01:43:09 ET
On Thursday, the U.S. Food and Drug Administration (FDA) approved Journavx (suzetrigine) 50 mg oral tablets, a first-in-class non-opioid analgesic for...
This is the key breakthrough AI still requires to reach superintelligence, according to those building it
A new study from researchers at Stanford University and Nvidia proposes a way for AI models to keep learning after deployment — without increasing i...
The geopolitical landscape of the Horn of Africa shifted significantly this week as the United States signaled a move toward the formal recognition of...
When initially experimenting with LLMs and agentic AI, software engineers at Notion AI applied advanced code generation, complex schemas, and heavy in...